Summit Therapeutics Inc. (SMMT) shareholders
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert W. Duggan | 555,736,060 | 75.20% | 13D (active) amendment | Sep 11, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SMMT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 32,786,348 | 4.11% | $477.70M | −3,604,715 | 2.39% |
| FMR LLC | 10,043,947 | 1.26% | $146.34M | −809,252 | 0.01% |
| State Street Corp | 9,536,796 | 1.20% | $138.95M | +2,508,636 | 0.00% |
| BlackRock, Inc. | 9,529,041 | 1.19% | $138.84M | −124,717 | 0.00% |
| Vanguard Capital Management LLC | 5,734,484 | 0.72% | $83.55M | +22,682 | 0.00% |
| UBS Group AG | 5,233,798 | 0.66% | $76.26M | +1,553,483 | 0.01% |
| Vanguard Portfolio Management LLC | 5,042,190 | 0.63% | $73.46M | −191,062 | 0.00% |
| Goldman Sachs Group Inc | 4,513,399 | 0.57% | $65.76M | +4,202,671 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 3,893,820 | 0.49% | $56.73M | −4,384,039 | 0.01% |
| Point72 Asset Management, L.P. | 3,697,803 | 0.46% | $53.88M | +2,913,617 | 0.06% |
| Geode Capital Management, LLC | 3,427,263 | 0.43% | $49.95M | +111,409 | 0.00% |
| Millennium Management LLC | 2,349,081 | 0.29% | $34.23M | +2,222,808 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,989,591 | 0.25% | $28.99M | New | 0.04% |
| Balyasny Asset Management L.P. | 1,904,254 | 0.24% | $27.74M | +1,355,919 | 0.03% |
| Citadel Advisors LLC | 1,725,716 | 0.22% | $25.14M | +1,283,973 | 0.00% |
| abrdn plc | 1,693,626 | 0.21% | $24.68M | +1,028,262 | 0.03% |
| Squarepoint Ops LLC | 1,590,736 | 0.20% | $23.18M | +976,859 | 0.03% |
| Morgan Stanley | 1,450,019 | 0.18% | $21.13M | −200,572 | 0.00% |
| Norges Bank | 1,382,519 | 0.17% | $20.14M | New | 0.00% |
| Logos Global Management LP | 1,350,000 | 0.17% | $19.67M | New | 0.85% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 242 | 136M | 17.0% | 58 / 97 | 57 / 35 | 32M | 15M |
| Q1 2026 | 222 | 119M | 14.9% | 58 / 83 | 49 / 37 | 25M | 13M |
| Q4 2025 | 206 | 118M | 14.8% | 35 / 74 | 66 / 60 | 23M | 8M |
| Q3 2025 | 232 | 103M | 12.9% | 51 / 79 | 67 / 42 | 14M | 8M |
| Q2 2025 | 226 | 98M | 12.3% | 67 / 64 | 72 / 42 | 20M | 21M |
| Q1 2025 | 202 | 99M | 12.4% | 38 / 73 | 69 / 31 | 12M | 5M |
| Q4 2024 | 196 | 93M | 11.6% | 62 / 76 | 36 / 26 | 13M | 5M |
| Q3 2024 | 164 | 85M | 10.6% | 65 / 50 | 33 / 18 | 26M | 6M |
| Q2 2024 | 121 | 72M | 9.1% | 40 / 19 | 47 / 20 | 35M | 14M |
| Q1 2024 | 103 | 51M | 6.4% | 18 / 40 | 28 / 10 | 19M | 2M |
| Q4 2023 | 95 | 33M | 4.2% | 10 / 36 | 20 / 6 | 5M | 4M |
| Q3 2023 | 91 | 32M | 4.1% | 8 / 33 | 22 / 13 | 2M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
186 funds held SMMT in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SMMT | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,453,137 | 0.93% | $108.59M | 1.01% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,707,548 | 0.46% | $54.02M | 0.00% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,667,317 | 0.33% | $38.86M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,652,737 | 0.33% | $46.53M | 0.05% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 2,531,231 | 0.32% | $36.88M | 0.31% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,778,361 | 0.22% | $25.91M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 1,691,382 | 0.21% | $24.64M | 0.04% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,067,669 | 0.13% | $18.73M | 0.36% | May 31, 2026 |
| iShares Biotechnology ETF | 955,912 | 0.12% | $13.93M | 0.15% | Jun 30, 2026 |
| Select Health Care Portfolio | 800,000 | 0.10% | $14.03M | 0.24% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 797,519 | 0.10% | $13.99M | 0.03% | May 31, 2026 |
| iShares Russell Mid-Cap Growth ETF | 791,547 | 0.10% | $11.53M | 0.05% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 778,918 | 0.10% | $13.66M | 0.05% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 659,283 | 0.08% | $11.56M | 0.05% | May 31, 2026 |
| iShares Russell Mid-Cap ETF | 554,624 | 0.07% | $8.08M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mahkam Zanganeh | Co-Chief Executive Officer, Director, 10% owner | 610,515,809 | 76.53% | Nov 16, 2026 |
| Robert W. Duggan | Co-Chief Executive Officer, Director, 10% owner | 610,515,809 | 76.53% | Nov 16, 2026 |
| Manmeet Singh Soni | COO and CFO, Director | 3,224,375 | 0.40% | Nov 16, 2026 |
| Bhaskar Anand | Chief Accounting Officer | 261,047 | 0.03% | Oct 14, 2026 |
| Jeff Huber | Director | 50,052 | 0.01% | Jan 6, 2026 |
| Mostafa Ronaghi | Director | – | – | Jan 6, 2026 |
| Kenneth A. Clark | Director | – | – | Jan 6, 2026 |
| Robert F. Booth | Director | – | – | Jan 6, 2026 |
| Yu Xia | Director | 32,057,147 | 4.02% | Jan 6, 2026 |
| Alessandra Cesano | Director | – | – | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Manmeet Singh Soni COO and CFO, Director | Nov 16, 2026 | Option exercise | +100,000 | $1.37 | $137.00K | 3,224,375 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Nov 16, 2026 | Option exercise | +500,000 | $1.06 | $530.00K | 531,000 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Nov 16, 2026 | Option exercise | +500,000 | $1.06 | $530.00K | 531,000 |
| Bhaskar Anand Chief Accounting Officer | Oct 8, 2026 | Award | +100,000 | – | – | 261,047 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Jun 12, 2026 | Buy | +3,810,000 | $13.12 | $49.99M | 573,883,879 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Jun 12, 2026 | Buy | +3,810,000 | $13.12 | $49.99M | 573,883,879 |
| Manmeet Singh Soni COO and CFO, Director | Jun 4, 2026 | Buy | +25,000 | $14.46 | $361.50K | 3,098,603 |
| Manmeet Singh Soni COO and CFO, Director | Jun 4, 2026 | Buy | +25,000 | $14.43 | $360.75K | 3,123,603 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Jun 4, 2026 | Buy | +100,000 | $14.60 | $1.46M | 25,824,474 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Jun 4, 2026 | Buy | +100,000 | $14.60 | $1.46M | 25,824,474 |
| Bhaskar Anand Chief Accounting Officer | Oct 21, 2025 | Award | +26,680 | $18.74 | $499.98K | 159,751 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +13,980,789 | $18.74 | $262.00M | 570,073,879 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Buy | +26,680 | $18.74 | $499.98K | 76,680 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +266,808 | $18.74 | $5.00M | 25,724,474 |
| Manmeet Singh Soni COO and CFO, Director | Oct 21, 2025 | Award | +53,361 | $18.74 | $999.99K | 3,073,603 |
| Yu Xia Director | Oct 21, 2025 | Buy | +533,617 | $18.74 | $10.00M | 32,057,147 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +13,980,789 | $18.74 | $262.00M | 570,073,879 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Buy | +26,680 | $18.74 | $499.98K | 76,680 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +266,808 | $18.74 | $5.00M | 25,724,474 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Sep 11, 2025 | Buy | +5,000 | $18.07 | $90.35K | 556,093,090 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Sep 11, 2025 | Buy | +5,000 | $18.07 | $90.35K | 556,093,090 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Sep 10, 2025 | Buy | +333,394 | $17.68 | $5.89M | 556,088,090 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Sep 10, 2025 | Buy | +333,394 | $17.68 | $5.89M | 556,088,090 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | May 30, 2025 | Option exercise | +74,545 | $2.64 | $196.80K | 555,754,696 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | May 30, 2025 | Option exercise | +74,545 | $2.64 | $196.80K | 555,754,696 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Apr 8, 2025 | Option exercise | +3,985,055 | $1.58 | $6.30M | 555,680,151 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Apr 8, 2025 | Option exercise | +3,985,055 | $1.58 | $6.30M | 555,680,151 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Oct 3, 2024 | Option exercise | +315,681 | $1.58 | $498.78K | 10,199,776 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Sep 11, 2024 | Award | +3,325,991 | $22.70 | $75.50M | 551,695,096 |
| Bhaskar Anand Chief Accounting Officer | Sep 11, 2024 | Award | +22,026 | $22.70 | $499.99K | 131,426 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Sep 11, 2024 | Award | +44,052 | $22.70 | $999.98K | 24,967,852 |
| Jeff Huber Director | Sep 11, 2024 | Award | +44,052 | $22.70 | $999.98K | 44,052 |
| Manmeet Singh Soni COO and CFO, Director | Sep 11, 2024 | Award | +44,052 | $22.70 | $999.98K | 3,020,242 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 27, 2024 | Buy | +26,000 | $3.72 | $96.72K | 520,814 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 27, 2024 | Buy | +34,321 | $3.72 | $127.67K | 24,923,800 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 27, 2024 | Buy | +20,000 | $3.71 | $74.20K | 50,000 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 26, 2024 | Buy | +30,000 | $3.75 | $112.50K | 30,000 |
| Ankur Dhingra Chief Financial Officer | Mar 26, 2024 | Buy | +100,000 | $3.75 | $375.00K | 354,958 |
| Ankur Dhingra Chief Financial Officer | Dec 13, 2023 | Buy | +19,700 | $2.17 | $42.75K | 254,958 |
| Ankur Dhingra Chief Financial Officer | Dec 13, 2023 | Buy | +700 | $2.15 | $1.51K | 235,258 |
| Mahkam Zanganeh Chief Executive Officer, Director | Dec 12, 2023 | Buy | +5,000 | $2.07 | $10.35K | 494,814 |
| Mahkam Zanganeh Chief Executive Officer, Director | Dec 11, 2023 | Option exercise | +489,814 | $1.44 | $705.33K | 489,814 |
| Mahkam Zanganeh Chief Executive Officer, Director | Dec 11, 2023 | Option exercise | +315,681 | $1.58 | $498.78K | 24,889,479 |
| Manmeet Singh Soni Chief Operating Officer, Director | Oct 13, 2023 | Buy | +2,976,190 | $1.68 | $5.00M | 2,976,190 |
| Mahkam Zanganeh Co-CEO & President, Director | Mar 8, 2023 | Buy | +6,748,629 | $1.05 | $7.09M | 9,884,095 |
| Mahkam Zanganeh Co-CEO & President, Director | Mar 8, 2023 | Buy | +16,778,415 | $1.05 | $17.62M | 24,573,798 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Mar 8, 2023 | Buy | +804,672 | $1.05 | $844.91K | 1,178,529 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Mar 8, 2023 | Buy | +6,748,629 | $1.05 | $7.09M | 9,884,095 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Mar 8, 2023 | Buy | +15,973,743 | $1.05 | $16.77M | 23,395,269 |
| Yu Xia Director | Mar 7, 2023 | Buy | +21,523,530 | $1.05 | $22.60M | 21,523,530 |
| Ankur Dhingra Chief Financial Officer | Mar 7, 2023 | Buy | +196,362 | $1.05 | $206.18K | 234,558 |
| Robert W. Duggan Chief Executive Officer, Director | Mar 6, 2023 | Buy | +376,489,880 | $1.05 | $395.31M | 552,354,161 |
| Yu Xia Director | Jan 17, 2023 | Buy | +10,000,000 | $2.51 | $25.10M | 10,000,000 |
| Mahkam Zanganeh Co-CEO & President, Director | Dec 6, 2022 | Other | +373,857 | – | – | 10,930,849 |
| Robert W. Duggan Chief Executive Officer, Director | Dec 6, 2022 | Other | +9,346,434 | – | – | 171,879,226 |
| Ankur Dhingra Chief Financial Officer | Aug 16, 2022 | Buy | +13,027 | $0.97 | $12.64K | 39,527 |
| Ankur Dhingra Chief Financial Officer | Aug 16, 2022 | Buy | +24,658 | $0.97 | $23.92K | 38,196 |
| Robert W. Duggan Chief Executive Officer, Director | Aug 16, 2022 | Buy | +94,849,203 | $0.97 | $92.00M | 162,532,792 |
| Mahkam Zanganeh Co-CEO & President, Director | Aug 16, 2022 | Buy | +1,030,925 | $0.97 | $1,000.00K | 3,135,466 |
| Mahkam Zanganeh Co-CEO & President, Director | Aug 16, 2022 | Buy | +184,430 | $0.97 | $178.90K | 359,969 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Summit Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,094,668 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?